Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SurModics, a provider of surface modification and drug delivery technologies to the healthcare industry, has announced that it is providing advanced hydrophilic coating technology for Elixir Medical's drug-eluting and bare metal stent systems, which are designed to optimize vessel scaffolding and localized drug delivery to provide a safe and effective treatment for cardiovascular patients.
Subscribe to our email newsletter
Elixir has conducted five first-in-human clinical studies evaluating the therapeutic effectiveness of the company’s Novolimus-eluting and Myolimus-eluting stent systems. Novolimus and Myolimus are macrocyclic lactones in the same family as Rapamycin.
The macrocyclic lactone drugs are said to be the most widely utilized drug family for drug-eluting stent applications and have an established safety and efficacy profile.
Motasim Sirhan, CEO of Elixir Medical, said: “We believe SurModics’ hydrophilic coating technology will enhance the deliverability of our bare metal and drug-eluting stent delivery systems, allowing us to better address physician and patient needs.”